Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005;3(3):195–212. doi: 10.1385/NCC:3:3:195

Approach to neuromuscular disorders in the intensive care unit

Kenneth C Gorson 1,
PMCID: PMC7101970  PMID: 16377830

Abstract

Neuromuscular disorders increasingly are recognized as a complication in patients in the intensive care unit (ICU) and represent a common cause of prolonged ventilator dependency. The distinct syndromes of critical illness myopathy, prolonged neuromuscular blockade, and critical illness polyneuropathy (CIP) may arise as a consequence of sepsis, multi-organ failure, and exposure to various medications—notably, intravenous corticosteroids and neuromuscular blocking agents—but the pathophysiology of these disorders remains poorly understood. More than one syndrome may occur simultaneously, and the distinctions may be difficult in a particular patient, but a specific diagnosis usually can be established after careful clinical, electrodiagnostic, and, when necessary, histological evaluation. For example, asthmatics requiring treatment with corticosteroids and neuromuscular blocking agents may develop an acute myopathy characterized by generalized weakness, preserved eye movements, elevated creatine kinase levels, and myopathic motor units on electromyography (EMG). Muscle biopsy demonstrates distinctive features of thick (myosin) filament loss on ultrastructural studies. Conversely, those with a prolonged ICU course that is complicated by episodes of sepsis with failure to wean from the ventilator, distal or generalized flaccid limb weakness, and areflexia probably have CIP. EMG in these patients demonstrates reduced or absent motor and sensory potentials with neurogenic motor units. Prolonged neuromuscular blockade most commonly occurs in patients with renal failure who have received prolonged infusions of neuromuscular blockers. There is severe flaccid, areflexic paralysis with normal sensation, facial weakness, and ophthalmoparesis that persists for days or weeks after the neuromuscular blockers have been discontinued. Repetitive nerve stimulation shows a decrement of the compound muscle action potential and, in most cases, establishes a disorder of neuromuscular transmission. With the recent epidemic of West Nile virus infection, a clinical syndrome of acute flaccid paralysis with several features indistinguishable from poliomyelitis has emerged. This article critically examines the clinical, electrophysiological, and pathological features of these and other acute neuromuscular syndromes that arise in the context of ICU care and summarizes the current understanding of the pathophysiology and treatment of these disorders.

Key Words: Critical illness myopathy, critical illness polyneuropathy, prolonged neuromuscular blockade, West Nile virus, acute flaccid paralysis, weakness, paralysis, intensive care unit

References

  • 1.Gorson KC, Ropper AH. Generalized paralysis in the intensive care unit: emphasis on the complications of neuromuscular blocking agents and corticosteroids. J Int Care Med. 1996;11:219–231. [Google Scholar]
  • 2.Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long term administration of vecuronium. N Engl J Med. 1992;327:524–528. doi: 10.1056/NEJM199208203270804. [DOI] [PubMed] [Google Scholar]
  • 3.De Jonghe B, Bastuji-Garin S, Sharshar T, Outin H, Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med. 2004;6:1117–1121. doi: 10.1007/s00134-004-2174-z. [DOI] [PubMed] [Google Scholar]
  • 4.Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, non-depolarizing blocking agents, or both. Neurology. 1992;42:2082–2087. doi: 10.1212/wnl.42.11.2082. [DOI] [PubMed] [Google Scholar]
  • 5.Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve. 1994;17:285–292. doi: 10.1002/mus.880170305. [DOI] [PubMed] [Google Scholar]
  • 6.Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropath Exp Neurol. 1993;52:387–398. doi: 10.1097/00005072-199307000-00006. [DOI] [PubMed] [Google Scholar]
  • 7.Barohn RJ, Jackson CE, Rogers SJ, Ridings LW, McVey AL. Prolonged paralysis due to non-depolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve. 1994;17:647–654. doi: 10.1002/mus.880170613. [DOI] [PubMed] [Google Scholar]
  • 8.Waclawik AJ, Sufit RL, Beinlich BR, Schutta HS. Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. Neuromusc Disord. 1992;2:19–26. doi: 10.1016/0960-8966(92)90022-X. [DOI] [PubMed] [Google Scholar]
  • 9.Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psych. 1984;47:1223–1231. doi: 10.1136/jnnp.47.11.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zochodne DW, Bolton CF, Gilbert JJ. Polyneuropathy in critical illness: pathologic features. Ann Neurol. 1985;18:160–160. [Google Scholar]
  • 11.Witt NJ, Bolton CF, Sibbald WJ. The incidence and early features of the polyneuropathy of critical illness. Neurology. 1985;35(Suppl 1):74–74. [Google Scholar]
  • 12.Bolton CF, Laverty DA, Brown JD, Witt NJ, Hahn AF, Sibbald WJ. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barre syndrome. J Neur Neurosurg Psych. 1986;49:563–573. doi: 10.1136/jnnp.49.5.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zochodne DW, Bolton CF, Wells GA, et al. Critical illness polyneuropathy. A complication of sepsis and multi-organ failure. Brain. 1987;110:819–842. doi: 10.1093/brain/110.4.819. [DOI] [PubMed] [Google Scholar]
  • 14.Bolton CF. Polyneuropathy as a cause of respiratory failure in critical illness. Int Crit Care Digest. 1988;77:8–8. [Google Scholar]
  • 15.Bolton CF. Electrophysiologic studies of critically ill patients. Muscle Nerve. 1987;10:129–135. doi: 10.1002/mus.880100205. [DOI] [PubMed] [Google Scholar]
  • 16.Coronel B, Mercatello A, Couturier JC, et al. Polyneuropathy: potential causes of difficult weaning. Crit Care Med. 1990;16:486–489. doi: 10.1097/00003246-199005000-00004. [DOI] [PubMed] [Google Scholar]
  • 17.Op de Coul AAW, Lambregts PCLA, Kleman J, van Puyenbroek MJE, Ter Laak HJ, Garbreels-Festen AAWM. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg. 1985;87:17–22. doi: 10.1016/0303-8467(85)90060-5. [DOI] [PubMed] [Google Scholar]
  • 18.Op de Coul AAW, Verheul GAM, Leyten ACM, Schellens RLLA, Teepen JLJM. Critical illness polyneuromyopathy after artificial respiration. Clin Neurol Neurosurg. 1991;93:27–33. doi: 10.1016/0303-8467(91)90005-A. [DOI] [PubMed] [Google Scholar]
  • 19.Couturier JC, Robert D, Monier P. Polynevrites compliquant des sejours prolonges en reanimation. A Propos de 11 cas d’etiologie encore inconnue. Lyon Med. 1984;252:274–279. [Google Scholar]
  • 20.Williams AC, Sturman S, Kelsey S, et al. The neuropathy of the critically ill. Br Med J. 1986;293:790–790. doi: 10.1136/bmj.293.6550.790-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Gorson KC, Ropper AH. Acute respiratory failure in neuropathy: a variant of critical illness polyneuropathy. Crit Care Med. 1993;21:267–271. doi: 10.1097/00003246-199302000-00020. [DOI] [PubMed] [Google Scholar]
  • 22.Raps EC, Bird SJ, Hansen-Flaschen JH. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clinics. 1994;10:799–813. [PubMed] [Google Scholar]
  • 23.van Mook WNKA, Hulsewe-Evers RPMG. Critical illness polyneuropathy. Opin Crit Care. 2002;8:302–310. doi: 10.1097/00075198-200208000-00006. [DOI] [PubMed] [Google Scholar]
  • 24.Hund E. Neurological complications of sepsis:critical illness polyneuropathy and myopathy. J Neurol. 2001;248:929–934. doi: 10.1007/s004150170043. [DOI] [PubMed] [Google Scholar]
  • 25.Gazmuri RJ, Hanif S, Wagner B. Persistent paralysis after vecuronium administration. N Engl J Med. 1992;327:1881–1881. doi: 10.1056/NEJM199212243272611. [DOI] [PubMed] [Google Scholar]
  • 26.Hansen-Flaschen J, Cowen J, Raps EC. Neuromuscular blockade in the intensive care unit. More than we bargained for. Am Rev Respir Dis. 1993;147:234–236. doi: 10.1164/ajrccm/147.1.234. [DOI] [PubMed] [Google Scholar]
  • 27.Marinelli WA, Leatherman JW. Neuromuscular disorders in the intensive care unit. Crit Care Clin. 2002;18:915–929. doi: 10.1016/S0749-0704(02)00020-9. [DOI] [PubMed] [Google Scholar]
  • 28.Chad DA, Lacomis D. Critically ill patients with newly acquired weakness: the clinicopathological spectrum. Ann Neurol. 1994;35:257–259. doi: 10.1002/ana.410350303. [DOI] [PubMed] [Google Scholar]
  • 29.Hund EF. Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. J Neurol Sci. 1996;136:10–16. doi: 10.1016/0022-510X(95)00310-X. [DOI] [PubMed] [Google Scholar]
  • 30.Hund E. Myopathy in critically ill patients. Crit Care Med. 1999;27:2544–2547. doi: 10.1097/00003246-199911000-00036. [DOI] [PubMed] [Google Scholar]
  • 31.Bolton CF. The polyneuropathy of critical illness. J Intensive Care Med. 1994;9:132–138. [Google Scholar]
  • 32.Leijten FSS, de Weerd AW. Critical illness polyneuropathy. A review of the literature, definition and pathophysiology. Clin Neurol Neurosurg. 1994;96:10–19. doi: 10.1016/0303-8467(94)90023-X. [DOI] [PubMed] [Google Scholar]
  • 33.Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med. 1996;24:1408–1416. doi: 10.1097/00003246-199608000-00022. [DOI] [PubMed] [Google Scholar]
  • 34.Zochodne DW, Bolton CF. Neuromuscular disorders in critical illness. Bailliere’s Clinical Neurology. 1996;5:645–671. [PubMed] [Google Scholar]
  • 35.Maher J, Rutledge F, Remtulla H, Parkes A, Bernardi L, Bolton CF. Neuromuscular disorders associated with failure to wean from the ventilator. Intensive Care Med. 1995;21:737–743. doi: 10.1007/BF01704741. [DOI] [PubMed] [Google Scholar]
  • 36.MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet. 1977;2:615–615. doi: 10.1016/S0140-6736(77)91471-4. [DOI] [PubMed] [Google Scholar]
  • 37.Van Marle W, Woods KL. Acute hydrocortisone myopathy. Br Med J. 1980;281:271–271. doi: 10.1136/bmj.281.6235.271-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Williams VJ, O’Hehir RE, Czarny D, Horne M. Bowes G Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis. 1988;137:460–463. doi: 10.1164/ajrccm/137.2.460. [DOI] [PubMed] [Google Scholar]
  • 39.Bachmann P., Gaussorgues P., Piperno D., et al. Acute myopathy after status asthmaticus. Presse Med. 1987;16:1486–1486. [PubMed] [Google Scholar]
  • 40.Kaplan PW, Rocha W, Sanders DB, D’Souza B, Spock A. Acute steroid induced tetraplegia following status asthmaticus. Pediatrics. 1986;78:121–123. [PubMed] [Google Scholar]
  • 41.Shee CD. Risk factors for hydrocortisone myopathy in acute severe asthma. Resp Med. 1990;84:229–233. doi: 10.1016/s0954-6111(08)80040-6. [DOI] [PubMed] [Google Scholar]
  • 42.Helliwell TR, Coakley JH, Wagenmakers AJM, Griffiths RD, et al. Necrotizing myopathy in critically ill patients. J Path. 1991;164:307–314. doi: 10.1002/path.1711640406. [DOI] [PubMed] [Google Scholar]
  • 43.Danon M.J., Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve. 1991;14:1131–1139. doi: 10.1002/mus.880141115. [DOI] [PubMed] [Google Scholar]
  • 44.Al-Lozi MT, Pestronk A, Yee WC, Flairs N, Cooper J. Rapidly evolving myopathy with myosin deficient muscle fibers. Ann Neurol. 1994;35:273–279. doi: 10.1002/ana.410350306. [DOI] [PubMed] [Google Scholar]
  • 45.Sher JH, Shafiq SA, Schutta HS. Acute myopathy with selective lysis of myosin filaments. Neurology. 1979;29:100–106. doi: 10.1212/wnl.29.1.100. [DOI] [PubMed] [Google Scholar]
  • 46.Subramony SH, Carpenter DE, Raju S, Pride M, Evans OB. Myopathy and prolonged neuromuscular blockade after a lung transplant. Crit Care Med. 1991;19:1580–1582. doi: 10.1097/00003246-199112000-00022. [DOI] [PubMed] [Google Scholar]
  • 47.Spitzer AR, Giancarlo T, Maher L, Awerbuch G, Bowles A. Neuromuscular causes of prolonged ventilator dependency. Muscle Nerve. 1992;15:682–686. doi: 10.1002/mus.880150609. [DOI] [PubMed] [Google Scholar]
  • 48.Zochodne DW, Ramsay DA. Acute quadriplegic myopathy (letter) Neurology. 1994;44:988–988. doi: 10.1212/wnl.44.5.988-a. [DOI] [PubMed] [Google Scholar]
  • 49.Wokke JHJ, Jennekens FGI, van den Oord CJM, Veldman H, van Gijn J. Histological investigations of muscle atrophy and end plates in two critically ill patients with generalized weakness. J Neurol Sci. 1988;88:95–106. doi: 10.1016/0022-510X(88)90208-0. [DOI] [PubMed] [Google Scholar]
  • 50.Apte-Kakade F. Rehabilitation of patients with quadriparesis after treatment of status asthmaticus with neuromuscular blocking agents and high dose corticosteroids. Arch Phys Med Rehabil. 1991;72:1024–1028. [PubMed] [Google Scholar]
  • 51.Sitwell LD, Weinshenker BG, Monpetit V, Reid D. Complete ophthalmoplegia as a complication of acute corticosteroid and pancuronium associated myopathy. Neurology. 1991;41:921–921. doi: 10.1212/wnl.41.6.921. [DOI] [PubMed] [Google Scholar]
  • 52.Banwell BL, Mildner RJ, Hassall AC, et al. Muscle weakness in critically ill children. Neurology. 2003;61:1779–1782. doi: 10.1212/01.wnl.0000098886.90030.67. [DOI] [PubMed] [Google Scholar]
  • 53.Douglass JA, Tuxen DV, Horne M, et al. Myopathy and severe asthma. Am Rev Respir Dis. 1992;146:517–519. doi: 10.1164/ajrccm/146.2.517. [DOI] [PubMed] [Google Scholar]
  • 54.Giostra E, Magistris MR, Pizzolato G, Cox J, Chevrolet JC. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Chest. 1994;106:210–220. doi: 10.1378/chest.106.1.210. [DOI] [PubMed] [Google Scholar]
  • 55.Zochodne DW, Bolton CF, Thompson RT, Driedger AA, Hahn AF, Gilbert JJ. Myopathy in critical illness. Muscle Nerve. 1986;9:652–652. [Google Scholar]
  • 56.Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. 1993;16:84–90. doi: 10.1002/mus.880160114. [DOI] [PubMed] [Google Scholar]
  • 57.Kupfer Y, Okrent DG, Twersky RA, Tessler S. Disuse atrophy in a ventilated patient with status asthmaticus receiving neuromuscular blockade. Crit Care Med. 1987;15:795–795. doi: 10.1097/00003246-198708000-00019. [DOI] [PubMed] [Google Scholar]
  • 58.Knox AJ, Mascie-Taylor BH, Meurs MF. Acute hydrocortisone myopathy in acute severe asthma. Thorax. 1986;41:411–411. doi: 10.1136/thx.41.5.411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Coakley JH, Nagendran K, Honavar M, Hinds CJ. Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Int Care Med. 1993;19:323–328. doi: 10.1007/BF01694705. [DOI] [PubMed] [Google Scholar]
  • 60.Coakley JH, Nagendran K, Ormerod IEC, Ferguson CN, Hinds CJ. Prolonged neurogenic weakness in patients requiring mechanical ventilation for acute airflow limitation. Chest. 1992;101:1413–1416. doi: 10.1378/chest.101.5.1413. [DOI] [PubMed] [Google Scholar]
  • 61.Margolis BD, Khachikian D, Friedman Y, Garrard C. Prolonged reversible quadriparesis in mechanically ventilated patients who received long term infusions of vecuronium. Chest. 1991;100:877–877. doi: 10.1378/chest.100.3.877. [DOI] [PubMed] [Google Scholar]
  • 62.Brun-Buisson C, Gherardi R. Hydrocortisone and pancuronium bromide: acute myopathy during status asthmaticus. Crit Care Med. 1988;16:731–731. [PubMed] [Google Scholar]
  • 63.Picado C, Montserrat J, Agusti-Vidal A. Muscle atrophy in severe exacerbation of asthma requiring mechanical ventilation. Respiration. 1988;53:201–203. doi: 10.1159/000195414. [DOI] [PubMed] [Google Scholar]
  • 64.Mackie G, Road J, Stewart H, Eisen A. Reversible paralysis with status asthmaticus, steroids and pancuronium. Clinical electrophysiological correlates. Neurology. 1993;43:A166. doi: 10.1002/(sici)1097-4598(199712)20:12<1587::aid-mus15>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  • 65.Hunter JM. New neuromuscular blocking drugs. N Engl J Med. 1995;332:1691–1699. doi: 10.1056/NEJM199506223322507. [DOI] [PubMed] [Google Scholar]
  • 66.Meyer KC, Prielipp RC, Grossman JE, Coursin DB. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg. 1994;78:772–774. doi: 10.1213/00000539-199404000-00027. [DOI] [PubMed] [Google Scholar]
  • 67.Krendel DA, Reid C, Roeske L. Persistent weakness following atracurium and corticosteroid administration. Muscle Nerve. 1994;17:1124–1124. [Google Scholar]
  • 68.Bella IR, Chad DA, Smith TW, et al. Ophthalmoplegia and quadriplegia in the wake of intensive therapy for status asthmaticus. Muscle Nerve. 1994;17:1122–1122. [Google Scholar]
  • 69.De Smet Y, Jaminet M, Jaeger U, et al. Acute corticosteroid myopathy following status asthmaticus. Rev Neurol. 1991;147:682–685. [PubMed] [Google Scholar]
  • 70.Griffin D, Fairman N, Cousin D, Rawsthorne L, Grossman JE. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest. 1992;102:510–514. doi: 10.1378/chest.102.2.510. [DOI] [PubMed] [Google Scholar]
  • 71.Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40:645–654. doi: 10.1002/ana.410400415. [DOI] [PubMed] [Google Scholar]
  • 72.Campellone JV, Lacomis D, Kramer DJ, van Cott AC, Giuliani MJ. Acute myopathy after liver transplantation. Neurology. 1998;50:46–53. doi: 10.1212/wnl.50.1.46. [DOI] [PubMed] [Google Scholar]
  • 73.Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve. 1998;21:610–617. doi: 10.1002/(SICI)1097-4598(199805)21:5&#x0003c;610::AID-MUS7&#x0003e;3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 74.Hanson P, Dive A, Brucher JM, Bisteau M, Dangoisse M, Deltombe T. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve. 1997;20:1371–1380. doi: 10.1002/(SICI)1097-4598(199711)20:11&#x0003c;1371::AID-MUS4&#x0003e;3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  • 75.Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve. 2000;23:1785–1788. doi: 10.1002/1097-4598(200012)23:12&#x0003c;1785::AID-MUS1&#x0003e;3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 76.Tsai LK, Sung-Tsang H, Chi-Chao C, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol. 2004;61:1669–1673. doi: 10.1001/archneur.61.11.1669. [DOI] [PubMed] [Google Scholar]
  • 77.Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet. 1996;347:1579–1582. doi: 10.1016/S0140-6736(96)91074-0. [DOI] [PubMed] [Google Scholar]
  • 78.Faragher MW, Day BJ, Dennett X. Critical care myopathy: an electrophysiological and histological study. Muscle Nerve. 1996;19:516–518. doi: 10.1002/(SICI)1097-4598(199604)19:4&#x0003c;516::AID-MUS11&#x0003e;3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 79.Sander HW, Golden M, Danon MJ. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve. 2002;26:499–505. doi: 10.1002/mus.10233. [DOI] [PubMed] [Google Scholar]
  • 80.Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve. 1997;20:665–673. doi: 10.1002/(SICI)1097-4598(199706)20:6&#x0003c;665::AID-MUS2&#x0003e;3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  • 81.Trojaborg W, Weimer LH, Hays AP. Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy—a reappraisal. Clin Neurophysiology. 2001;112:1586–1593. doi: 10.1016/S1388-2457(01)00572-7. [DOI] [PubMed] [Google Scholar]
  • 82.Bednarik J, Zdenek L, Vondracek P. Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Int Care Med 2003;1505–1514. [DOI] [PubMed]
  • 83.Bizzarri-Schmid ND, Desai SP. Prolonged neuromuscular blockade with atracurium. Can Anaesth Soc J. 1986;33:209–212. doi: 10.1007/BF03010832. [DOI] [PubMed] [Google Scholar]
  • 84.Danon MJ, Kumarasiri M, Giometti CS, Etlinger J, Zeman R. Steroid induced quadriplegic myopathy with thick filament (myosin) loss: biochemical studies and the 1st autopsy report. Neurology. 1998;50:A205. [Google Scholar]
  • 85.Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence of calpain-mediated proteolysis. Muscle Nerve. 1997;20:316–322. doi: 10.1002/(SICI)1097-4598(199703)20:3&#x0003c;316::AID-MUS8&#x0003e;3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 86.Hoke A, Rewcastle NB, Zochodne DW. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci. 1999;26:325–329. doi: 10.1017/s0317167100000482. [DOI] [PubMed] [Google Scholar]
  • 87.Deconinck N, van Parijs V, Beckers-Bleukx G, van den Bergh P. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromusc Dis. 1998;8:186–192. doi: 10.1016/S0960-8966(98)00003-0. [DOI] [PubMed] [Google Scholar]
  • 88.Gutmann L, Blumenthal D, Gutmann L, Schochet SS. Acute type II myofiber atrophy in critical illness. Neurology. 1996;46:819–821. doi: 10.1212/wnl.46.3.819. [DOI] [PubMed] [Google Scholar]
  • 89.Bazzi P, Moggio M, Prelle A, et al. Critically ill patients: immunological evidence of inflammation of muscle biopsy. Clin Neuropathol. 1999;18:23–30. [PubMed] [Google Scholar]
  • 90.Matsumoto N, Nakamura T, Yasui Y, Torii J. Analysis of muscle proteins in acute quadriplegic myopathy. Muscle Nerve. 2000;23:1270–1276. doi: 10.1002/1097-4598(200008)23:8&#x0003c;1270::AID-MUS18&#x0003e;3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 91.de Letter MA, van Doorn PA, Savelkoul HF, et al. Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol. 2000;106:206–213. doi: 10.1016/S0165-5728(99)00252-0. [DOI] [PubMed] [Google Scholar]
  • 92.Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular level. Crit Care Med. 2000;28:34–45. doi: 10.1097/00003246-200001000-00006. [DOI] [PubMed] [Google Scholar]
  • 93.Yarom R, Sphira Y. Myosin degeneration in a congenital myopathy. Arch Neurol. 1977;34:114–114. doi: 10.1001/archneur.1977.00500140068014. [DOI] [PubMed] [Google Scholar]
  • 94.Carpenter S, Karpati G. Pathology of skeletal muscle. New York: Churchill and Livingstone; 1984. [Google Scholar]
  • 95.Ruff RL. Acute illness myopathy. Neurology. 1996;46:600–600. doi: 10.1212/wnl.46.3.600. [DOI] [PubMed] [Google Scholar]
  • 96.DuBois DC, Almon RR. A possible role for glucocorticoids in denervation atrophy. Muscle Nerve. 1981;4:370–373. doi: 10.1002/mus.880040504. [DOI] [PubMed] [Google Scholar]
  • 97.Rouleau G, Karpati G, Carpenter S, Soza M, Prescott S, Holland P. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve. 1987;10:428–438. doi: 10.1002/mus.880100509. [DOI] [PubMed] [Google Scholar]
  • 98.Carpenter S, Massa R, Karpati G. Depletion and reconstitution of thick myofilaments in steroid treated rat solei after denervation and reinnervation. J Neurol Sci. 1990;98:377–377. [Google Scholar]
  • 99.Massa R, Carpenter S, Holland P, Karpati G. Loss and renewal of thick myofilaments in glucocorticoid treated rat soleus after denervation and reinnervation. Muscle Nerve. 1992;15:1290–1298. doi: 10.1002/mus.880151112. [DOI] [PubMed] [Google Scholar]
  • 100.Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol. 1993;264:668–676. doi: 10.1152/ajpendo.1993.264.4.E668. [DOI] [PubMed] [Google Scholar]
  • 101.Minetti C, Hirano M, Morreale G, et al. Ubiquitin expression in acute steroid myopathy with loss of myosin thick filaments. Muscle Nerve. 1996;19:94–96. doi: 10.1002/(SICI)1097-4598(199601)19:1&#x0003c;94::AID-MUS14&#x0003e;3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 102.Di Giovanni S, Molon A, Broccolini A, et al. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol. 2004;55:195–206. doi: 10.1002/ana.10811. [DOI] [PubMed] [Google Scholar]
  • 103.Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psych. 1993;56:702–704. doi: 10.1136/jnnp.56.6.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol. 1998;43:171–179. doi: 10.1002/ana.410430207. [DOI] [PubMed] [Google Scholar]
  • 105.Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology. 1996;46:731–736. doi: 10.1212/wnl.46.3.731. [DOI] [PubMed] [Google Scholar]
  • 106.van der Hoeven JH. Decline of muscle fiber conduction velocity during short-term high dose methylprednisolone therapy. Muscle Nerve. 1996;19:100–102. doi: 10.1002/(SICI)1097-4598(199601)19:1&#x0003c;100::AID-MUS16&#x0003e;3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  • 107.Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol. 2001;50:26–33. doi: 10.1002/ana.1016. [DOI] [PubMed] [Google Scholar]
  • 108.Filatov GN, Rich MM. Hyperpolarized shifts in the voltage dependence of fast activation of Nav1.4 and Nav1.5 in a rat model of critical illness myopathy. J Physiol. 2004;559:813–820. doi: 10.1113/jphysiol.2004.062349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Friedrich O, Hund E, Weber C, Hacke W, Fink RH. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol. 2004;251:53–65. doi: 10.1007/s00415-004-0272-z. [DOI] [PubMed] [Google Scholar]
  • 110.Clowes GHA, George BC, Villee CA. Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. N Engl J Med. 1983;308:545–552. doi: 10.1056/NEJM198303103081001. [DOI] [PubMed] [Google Scholar]
  • 111.Ruff RL, Secrist D. Inhibitors of prostaglandin synthesis or Cathepsin B prevent muscle wasting due to sepsis in the rat. J Clin Invest. 1984;73:1483–1486. doi: 10.1172/JCI111352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Arellano F, Krupp P. Muscular disorders associated with cyclosporin. Lancet 1991;:337–915. [DOI] [PubMed]
  • 113.Chassagne P, Mejjad O, Moore N, et al. Myopathy as possible side-effect of cyclosporin. Lancet. 1989;2:1104–1104. doi: 10.1016/S0140-6736(89)91123-9. [DOI] [PubMed] [Google Scholar]
  • 114.Wijdicks EFM. Neurology of critical illness. Philadelphia: F. A. Davis Co.; 1995. [Google Scholar]
  • 115.Rosenow EC, Engel AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med. 1978;64:485–491. doi: 10.1016/0002-9343(78)90235-8. [DOI] [PubMed] [Google Scholar]
  • 116.Barohn RJ, Clanton TL, Sahenk Z, Mendell JR. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies. Neurology. 1990;40:103–106. doi: 10.1159/000138648. [DOI] [PubMed] [Google Scholar]
  • 117.DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98:637–666. doi: 10.1093/brain/98.4.637. [DOI] [PubMed] [Google Scholar]
  • 118.Jammes Y, Pouget J, Grimaud C, Serratrice G. Pulmonary function and electromyographic study of respiratory muscles in myotonic dystrophy. Muscle Nerve. 1985;8:586–594. doi: 10.1002/mus.880080708. [DOI] [PubMed] [Google Scholar]
  • 119.Belafsky MA, Klawans HL. Prolonged neuromuscular blockade with pancuronium bromide in a young healthy woman. Anesthesiology. 1974;40:295–295. doi: 10.1097/00000542-197403000-00018. [DOI] [PubMed] [Google Scholar]
  • 120.Shanks AB, Long T, Aitkenhead AR. Prolonged neuromuscular blockade following vecuronium. Br J Anaesth. 1985;57:807–810. doi: 10.1093/bja/57.8.807. [DOI] [PubMed] [Google Scholar]
  • 121.Haas JL, Shaefer MS, Miwa J, Wood RP, Shaw BW. Prolonged paralysis associated with long-term pancuronium use. Pharmacotherapy. 1989;9:154–157. doi: 10.1002/j.1875-9114.1989.tb04121.x. [DOI] [PubMed] [Google Scholar]
  • 122.Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long term infusion of vecuronium bromide in the intensive care unit. Crit Care Med. 1990;18:1177–1179. doi: 10.1097/00003246-199010000-00025. [DOI] [PubMed] [Google Scholar]
  • 123.Rossiter A, Souney PF, McGowan S, Carvajal P. Pancuronium-induced prolonged neuromuscular blockade. Crit Care Med. 1991;19:1583–1587. doi: 10.1097/00003246-199112000-00023. [DOI] [PubMed] [Google Scholar]
  • 124.Lagasse RS, Katz RI, Petersen M, Jacobson MJ, Poppers PJ. Prolonged neuromuscular blockade following vecuronium infusion. J Clin Anesth. 1990;2:269–271. doi: 10.1016/0952-8180(90)90107-E. [DOI] [PubMed] [Google Scholar]
  • 125.Gooch JL, Suchyta MR, Balbierz JM, Petajan JH, Clemmer TP. Prolonged paralysis after treatment with neuromuscular junction blocking agents. Crit Care Med. 1991;19:1125–1131. doi: 10.1097/00003246-199109000-00006. [DOI] [PubMed] [Google Scholar]
  • 126.Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD. Prolonged neuromuscular blockade after long term administration of vecuronium in two critically ill patients. Anesthesiology. 1990;72:566–570. doi: 10.1097/00000542-199003000-00030. [DOI] [PubMed] [Google Scholar]
  • 127.Vanderheyden BA, Reynolds HN, Gerold KB, Emanuel T. Prolonged paralysis after long term vecuronium infusion. Crit Care Med. 1992;20:304–307. doi: 10.1097/00003246-199202000-00019. [DOI] [PubMed] [Google Scholar]
  • 128.Feldman SA, Levi JA. Prolonged paresis following gallamine. Brit J Anaesth. 1963;35:804–806. doi: 10.1093/bja/35.12.804. [DOI] [PubMed] [Google Scholar]
  • 129.Vandenbrom RHG, Wierda JMKH. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology. 1988;69:996–996. doi: 10.1097/00000542-198812000-00040. [DOI] [PubMed] [Google Scholar]
  • 130.Gooch JL, Moore MH, Ryser DK. Prolonged paralysis after neuromuscular junction blockade: case reports and electrodiagnostic findings. Arch Phys Med Rehabil. 1993;74:1007–1011. [PubMed] [Google Scholar]
  • 131.Torres CF, Maniscalco WM, Agostinelli T. Muscle weakness and atrophy following prolonged paralysis with pancuronium bromide in neonates. Ann Neurol. 1985;18:403–403. [Google Scholar]
  • 132.Smith CL, Hunter JM, Jones RS. Vecuronium infusions in patients with renal failure in an ITU. Anaesthesia. 1987;42:387–393. doi: 10.1111/j.1365-2044.1987.tb03980.x. [DOI] [PubMed] [Google Scholar]
  • 133.Sinclair JF, Malcolm GA, Stephenson JBP, Halworth D. Prolonged neuromuscular blockade in an infant. Anaesthesia. 1987;42:1020–1020. doi: 10.1111/j.1365-2044.1987.tb05389.x. [DOI] [PubMed] [Google Scholar]
  • 134.Camp CE, Tessem J, Adenwala J, Joyce TH. Vecuronium and prolonged neuromuscular blockade in postpartum patients. Anesthesiology. 1987;67:1006–1008. doi: 10.1097/00000542-198712000-00028. [DOI] [PubMed] [Google Scholar]
  • 135.Benzing G, Iannaccone ST, Bove KE, Keebler PJ, Shockley LI. Prolonged myasthenic syndrome after one week of muscle relaxants. Pediatr Neurol. 1990;6:190–196. doi: 10.1016/0887-8994(90)90062-6. [DOI] [PubMed] [Google Scholar]
  • 136.Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. JAMA. 1991;266:2870–2875. doi: 10.1001/jama.266.20.2870. [DOI] [PubMed] [Google Scholar]
  • 137.Klessig HT, Geiger HJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologists in the use of muscle relaxants. Crit Care Med. 1992;20:1441–1445. doi: 10.1097/00003246-199209000-00024. [DOI] [PubMed] [Google Scholar]
  • 138.Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142–156. doi: 10.1097/00003246-200201000-00021. [DOI] [PubMed] [Google Scholar]
  • 139.Marshall IG, Gibb AJ, Durant NN. Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (ORG NC 45) and its potential metabolites in the anaesthetized cat. Br J Anaesth. 1983;55:703–714. doi: 10.1093/bja/55.8.703. [DOI] [PubMed] [Google Scholar]
  • 140.Bencini AF, Houwertjes MC, Agoston S. Effects of hepatic uptake of vecuronium bromide and its putative metabolites on the neuromuscular blocking actions in the cat. Br J Anaesth. 1985;57:789–795. doi: 10.1093/bja/57.8.789. [DOI] [PubMed] [Google Scholar]
  • 141.Clarens DM, Kelly KJ, Gilliland SS, Kohls PK, Nahum A, Vance-Bryan K. A retrospective analysis of long-term use of non-depolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection. Pharmacotherapy. 1993;13:647–655. [PubMed] [Google Scholar]
  • 142.Crosby E, Robblee JA. Cyclosporine-pancuronium interaction in a patient with a renal allograft. Can J Anaesth. 1988;35:300–302. doi: 10.1007/BF03010635. [DOI] [PubMed] [Google Scholar]
  • 143.Kupfer Y, Namba T, Kaldawi E, Tessler S. Prolonged weakness after long term infusion of vecuronium bromide. Ann Int Med. 1992;117:484–486. doi: 10.7326/0003-4819-117-6-484. [DOI] [PubMed] [Google Scholar]
  • 144.Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J. Distribution, elimination and action of vecuronium in the elderly. Anesth Analg. 1991;73:39–42. doi: 10.1213/00000539-199107000-00008. [DOI] [PubMed] [Google Scholar]
  • 145.Dundee JW, Gray TC. Resistance to D-tubocurarine chloride in the presence of liver damage. Lancet. 1953;2:16–16. doi: 10.1016/S0140-6736(53)90006-3. [DOI] [PubMed] [Google Scholar]
  • 146.Erkola O. Complications of neuromuscular blockers: interaction with concurrent medications and other neuromuscular blockers. Anaesth Clin North Am. 1993;11:427–444. [Google Scholar]
  • 147.Durbin CG. Neuromuscular blocking agents and sedative drugs. Crit Care Clin. 1991;7:489–506. [PubMed] [Google Scholar]
  • 148.de Lemos JM, Carr RR, Shalansky KF, Bevan DR, Ronco JJ. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med. 1999;27:2648–2655. doi: 10.1097/00003246-199912000-00007. [DOI] [PubMed] [Google Scholar]
  • 149.Aggarwal A, Gutmann L, Gutierrez A. Electrophysiological features of vecuronium induced prolonged neuromuscular blockade. Muscle Nerve. 1994;2:251–252. [PubMed] [Google Scholar]
  • 150.Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve. 1992;15:720–724. doi: 10.1002/mus.880150616. [DOI] [PubMed] [Google Scholar]
  • 151.Baumann MH, McAlpin BW, Brown K, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest. 2004;126:1267–1273. doi: 10.1378/chest.126.4.1267. [DOI] [PubMed] [Google Scholar]
  • 152.Wilson RW, Ward D, Johns TR. Corticosteroids: a direct effect at the neuromuscular junction. Neurology. 1974;24:1091–1095. doi: 10.1212/wnl.24.11.1091. [DOI] [PubMed] [Google Scholar]
  • 153.Van Wilgenburg H. The effect of prednisolone on neuromuscular transmission in the rat diaphragm. Eur J Pharm. 1979;55:355–361. doi: 10.1016/0014-2999(79)90109-2. [DOI] [PubMed] [Google Scholar]
  • 154.Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986;36:729–732. doi: 10.1212/wnl.36.5.729. [DOI] [PubMed] [Google Scholar]
  • 155.Segura RP, Tsairis P. Physiological effect of intravenous corticosteroids on the human neuromuscular junction. Electroenceph Clin Neurophsyiol. 1978;45:19P. [Google Scholar]
  • 156.Schwartz AE, Matteo RS, Ornstein E, Silverberg PA. Acute steroid therapy does not alter non-depolarizing muscle relaxant effects in humans. Anesthesiology. 1986;65:326–327. doi: 10.1097/00000542-198609001-00324. [DOI] [PubMed] [Google Scholar]
  • 157.Arts WF, Oosterhuis HJ. Effects of prednisolone on neuromuscular blocking in mice in vivo. Neurology. 1975;25:1088–1090. doi: 10.1212/wnl.25.11.1088. [DOI] [PubMed] [Google Scholar]
  • 158.Leeuwin RS, Wolters ECMJ. Effects of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. Neurology. 1977;27:171–177. doi: 10.1212/wnl.27.2.171. [DOI] [PubMed] [Google Scholar]
  • 159.Leeuwin RS, Veldsema-Currie RD, VanWilgenburg H, Ottenhof M. Effects of corticosteroids on neuromuscular blocking actions of D-tubocurarine. Eur J Pharm. 1981;69:165–173. doi: 10.1016/0014-2999(81)90411-8. [DOI] [PubMed] [Google Scholar]
  • 160.Durant NN, Briscoe JR, Katz RL. The effects of acute and chronic hydrocortisone treatment on neuromuscular blockade in the anesthetized cat. Anesthesiology. 1984;61:144–150. doi: 10.1097/00000542-198409001-00144. [DOI] [PubMed] [Google Scholar]
  • 161.Kindler CM, Verotta D, Gray AT, Gropper MA, Yost CS. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology. 2000;92:821–832. doi: 10.1097/00000542-200003000-00026. [DOI] [PubMed] [Google Scholar]
  • 162.Dodson B, Kelly BJ, Braswell LM, Cohen NH. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: an investigation of the molecular mechanism of prolonged paralysis. Crit Care Med. 1995;23:815–821. doi: 10.1097/00003246-199505000-00007. [DOI] [PubMed] [Google Scholar]
  • 163.Pauker SG, Kopelman RI. Weak reasoning: diagnosis by drug reaction. N Eng J Med. 1993;328:336–339. doi: 10.1056/NEJM199302043280509. [DOI] [PubMed] [Google Scholar]
  • 164.Maher J, Bolton CF, Parkes T. Isolated respiratory denervation in myasthenia gravis. Can J Neurol Sci. 1992;19:297–297. [Google Scholar]
  • 165.Nagappan R, Kletcho S. Myasthenia gravis presenting as respiratory failure. New Zealand Med J. 1992;105:152–152. [PubMed] [Google Scholar]
  • 166.Nicolle MW, Stewart JD, Remtulla H, Chen R, Bolton CF. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve. 1996;19:1238–1333. doi: 10.1002/(SICI)1097-4598(199610)19:10&#x0003c;1328::AID-MUS10&#x0003e;3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 167.Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Eng J Med. 1979;301:409–413. doi: 10.1056/NEJM197908233010805. [DOI] [PubMed] [Google Scholar]
  • 168.Warner WA, Sanders E. Neuromuscular blockade associated with gentamycin. JAMA. 1971;215:1153–1153. doi: 10.1001/jama.215.7.1153. [DOI] [PubMed] [Google Scholar]
  • 169.Witt NJ, Zochodne DW, Bolton CF, et al. Peripheral nerve function in sepsis and multi-organ failure. Chest. 1991;99:176–184. doi: 10.1378/chest.99.1.176. [DOI] [PubMed] [Google Scholar]
  • 170.Berek K, Margreiter J, Willeit J, Berek A, Schmutzhard E, Mutz NJ. Polyneuropathies in critically ill patients: a prospective evaluation. Intensive Care Med. 1996;22:849–855. doi: 10.1007/BF02044106. [DOI] [PubMed] [Google Scholar]
  • 171.Tepper M, Rakic S, Haas JA, Woittiez AJ. Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med. 2000;56:211–214. doi: 10.1016/S0300-2977(00)00019-X. [DOI] [PubMed] [Google Scholar]
  • 172.Leijten FS, Harinck-de Weerd JE, Poortvliet DCJ, de Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA. 1995;274:1221–1225. doi: 10.1001/jama.274.15.1221. [DOI] [PubMed] [Google Scholar]
  • 173.Zifko UA. Long-term outcome of critical illness polyneuropathy. Muscle Nerve Suppl. 2000;9:S49–S52. doi: 10.1002/1097-4598(2000)999:9&#x0003c;::AID-MUS9&#x0003e;3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 174.de Seze M, Petit H, Wiart L, et al. Critical illness polyneuropathy. A 2-year followup study in 19 severe cases. Eur Neurol. 2000;43:61–69. doi: 10.1159/000008137. [DOI] [PubMed] [Google Scholar]
  • 175.Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiological abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. 2003;31:1012–1016. doi: 10.1097/01.CCM.0000053651.38421.D9. [DOI] [PubMed] [Google Scholar]
  • 176.Leijten FSS, De Weerd AW, Poortvliet DCJ, Ulrich C, Harinck-De Weerd JE. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med. 1996;22:856–861. doi: 10.1007/BF02044107. [DOI] [PubMed] [Google Scholar]
  • 177.Zifko UA, Zipko HT, Bolton CF. Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci. 1998;159:186–193. doi: 10.1016/S0022-510X(98)00164-6. [DOI] [PubMed] [Google Scholar]
  • 178.Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001;27:1288–1296. doi: 10.1007/s001340101009. [DOI] [PubMed] [Google Scholar]
  • 179.De Letter MAC, Schmitz PIM, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2001;29:2281–2286. doi: 10.1097/00003246-200112000-00008. [DOI] [PubMed] [Google Scholar]
  • 180.van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367. doi: 10.1056/NEJMoa011300. [DOI] [PubMed] [Google Scholar]
  • 181.Hund E, Genzwurker H, Bohrer H, Jakob H, Thiele R, Hacke W. Predominant involvement of motor fibers in patients with critical illness polyneuropathy. Br J Anaesth. 1997;78:274–278. doi: 10.1093/bja/78.3.274. [DOI] [PubMed] [Google Scholar]
  • 182.Schwarz J, Planck J, Briegel J, Straube A. Single fiber electromyography, nerve conduction studies, and conventional electromyography in patients with critical illness polyneuropathy: evidence for a lesion of terminal axons. Muscle Nerve. 1997;20:696–701. doi: 10.1002/(SICI)1097-4598(199706)20:6&#x0003c;696::AID-MUS6&#x0003e;3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 183.Coakley JH, Nagendran K, Yarwood GD, Honavar M, Hinds CJ. Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med. 1998;24:801–807. doi: 10.1007/s001340050669. [DOI] [PubMed] [Google Scholar]
  • 184.Bolton CF. Assessment of respiratory function in the intensive care unit. Can J Neurol Sci. 1994;21:S28–S34. [PubMed] [Google Scholar]
  • 185.Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol (Berl) 2003;106:75–82. doi: 10.1007/s00401-003-0704-3. [DOI] [PubMed] [Google Scholar]
  • 186.Waldhausen E, Mingers B, Lippers P, Keser G. Critical illness polyneuropathy due to parenteral nutrition. Int Care Med. 1997;23:922–922. [PubMed] [Google Scholar]
  • 187.Marino PI, Millili JJ. Possible role of dietary lipids in critical illness polyneuropathy. Int Care Med. 1998;24:87–87. doi: 10.1007/PL00003757. [DOI] [PubMed] [Google Scholar]
  • 188.Fong Y. Cachectin/TNF or II-1a induces cachexia with redistribution of body proteins. Am J Physiol. 1989;256:659–665. doi: 10.1152/ajpregu.1989.256.3.R659. [DOI] [PubMed] [Google Scholar]
  • 189.Verheul GAM, de Jongh-Leuvenink J, Op de Coul AAW, van Landeghem AAJ, van Puyenbroek MJE. Tumor necrosis factor and interleukin-6 in critical illness polyneuropathy. Clin Neurol Neurosurg. 1994;96:300–304. doi: 10.1016/0303-8467(94)90118-X. [DOI] [PubMed] [Google Scholar]
  • 190.Druschky A, Herkert M, Radespiel-Troger M, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med. 2001;27:686–693. doi: 10.1007/s001340100890. [DOI] [PubMed] [Google Scholar]
  • 191.Hund F, Herbert M, Becker CM, Hacke W. A humoral neurotoxic factor in sera of patients with critical illness polyneuropathy. Ann Neurol. 1996;40:539–539. [Google Scholar]
  • 192.Van den Berge G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64:1348–1353. doi: 10.1212/01.WNL.0000158442.08857.FC. [DOI] [PubMed] [Google Scholar]
  • 193.Wijdicks EFM, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve. 1994;17:1494–1494. [PubMed] [Google Scholar]
  • 194.Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med. 1997;23:1144–1149. doi: 10.1007/s001340050471. [DOI] [PubMed] [Google Scholar]
  • 195.Wiederholt WC, Mulder DW, Lambert EH. The Landry-Guillain-Barre-Strohl syndrome or polyradiculopathy. Historical review, report on 97 patients and present concepts. Mayo Clin Proc. 1964;39:427–451. [PubMed] [Google Scholar]
  • 196.Arnason BGW, Soliven B. Acute inflammatory demyelinating polyneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Podulso JF, editors. Peripheral Neuropathy. Philadelphia: WB Saunders; 1993. pp. 1437–1497. [Google Scholar]
  • 197.Millar AB, Clarke SW, Davis SN, Gross MLP. Prolonged ventilation in acute severe asthma caused by the Guillain-Barre’-Strohl syndrome. J Royal Soc Med. 1984;77:965–965. doi: 10.1177/014107688407701117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 198.Hamilton RJ, Puckett R, Bazemore WC. Ventilator dependence in acute severe asthma due to a variant presentation of Guillain-Barre syndrome. Chest. 1989;96:1205–1205. doi: 10.1378/chest.96.5.1205. [DOI] [PubMed] [Google Scholar]
  • 199.Preston DC, Logigian EL. Guillain-Barre syndrome during high dose methylprednisolone therapy. Muscle Nerve. 1991;14:378–378. [PubMed] [Google Scholar]
  • 200.Terasako K, Seo N, Murayama T, Kai T, Hirata S, Fujiwara T. Are immune mechanisms involved in critical illness polyneuropathy? Int Care Med. 1995;21:96–96. doi: 10.1007/BF02425166. [DOI] [PubMed] [Google Scholar]
  • 201.Windebank AJ, Bonkovsky HL. Porphyric neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral Neuropathy. Philadelphia: WB Saunders; 1993. pp. 1161–1169. [Google Scholar]
  • 202.Zochodne DW, Semmler RT, Ludwin SK, Auer R. Acute fulminant symmetrical vasculitic polyneuropathy: need for early biopsy. Clin Neuropathol. 1996;15:113–115. [PubMed] [Google Scholar]
  • 203.Chen R, Grand’Maison F, Strong MJ, et al. Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study. J Neurol Neurosurgery Psychiatry. 1996;60:455–458. doi: 10.1136/jnnp.60.4.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204.Martin AA, Gubler DJ. West Nile Encephalitis: an emerging disease in the United States. Clin Inf Dis. 2001;33:1713–1719. doi: 10.1086/322700. [DOI] [PubMed] [Google Scholar]
  • 205.Huhn GD, Sejvar JJ, Montgomery SP, Dworkin MS. West Nile virus in the United States: An update on an emerging infectious disease. Am Fam Physician. 2003;68:653–660. [PubMed] [Google Scholar]
  • 206.Solomon T, Ooi MH, Beasley DWC, Mallewa M. West Nile encephalitis. BMJ. 2003;326:865–869. doi: 10.1136/bmj.326.7394.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 207.Update: investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion—Michigan, 2002. MMWR 2002;51:879. [PubMed]
  • 208.Laboratory-acquired West Nile virus infections—United States MMWR. 2002;51:877–878. [PubMed] [Google Scholar]
  • 209.Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358:261–264. doi: 10.1016/S0140-6736(01)05480-0. [DOI] [PubMed] [Google Scholar]
  • 210.Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–1814. doi: 10.1056/NEJM200106143442401. [DOI] [PubMed] [Google Scholar]
  • 211.Jeha LE, Sila CA, Lederman RJ, et al. West Nile virus infection. A new acute paralytic illness. Neurology. 2003;61:55–59. doi: 10.1212/01.wnl.0000073617.08185.0a. [DOI] [PubMed] [Google Scholar]
  • 212.Leis AA, Stokic DS. Neuromuscular manifestations of human West Nile virus infection. Curr Treat Options Neurol. 2005;7:15–22. doi: 10.1007/s11940-005-0002-6. [DOI] [PubMed] [Google Scholar]
  • 213.Leis AA, Stokic DS, Polk JL, Dostrow V, Winkelmann M. A poliomyelitis-like syndrome from West Nile virus infection. N Eng J Med. 2002;347:1279–1280. doi: 10.1056/NEJM2002c021587. [DOI] [PubMed] [Google Scholar]
  • 214.Agamanolis DP, Leslie MJ, Caveny EA, Guarner J, Shieh WJ, Zaki SR. Neuropathological findings in West Nile virus encephalitis: a case report. Ann Neurol. 2003;54:547–551. doi: 10.1002/ana.10731. [DOI] [PubMed] [Google Scholar]
  • 215.Leis AA, Stokic DS, Webb RM, Slavinski SA, Fratkin J. Clinical spectrum of muscle weakness in human West Nile virus infection. Muscle Nerve. 2003;28:302–308. doi: 10.1002/mus.10440. [DOI] [PubMed] [Google Scholar]
  • 216.Doron SI, Dashe JF, Adelman LS, Brown WF, Werner BG, Hadley S. Histologically proven poliomyelitis with quadriplegiaand loss of brainstem function due to West Nile virus infection. Clin Inf Dis. 2003;37:74–77. doi: 10.1086/377177. [DOI] [PubMed] [Google Scholar]
  • 217.Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc. 2003;78:1137–1144. doi: 10.4065/78.9.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Peterson LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137:173–179. doi: 10.7326/0003-4819-137-3-200208060-00009. [DOI] [PubMed] [Google Scholar]
  • 219.Li J, Loeb JA, Shy ME, et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol. 2003;53:703–710. doi: 10.1002/ana.10575. [DOI] [PubMed] [Google Scholar]
  • 220.Burton JM, Kern RZ, Halliday W, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci. 2004;31:185–193. doi: 10.1017/s0317167100053828. [DOI] [PubMed] [Google Scholar]
  • 221.Gorson KC, Ropper AH. Nonpoliovirus poliomyelitis simulating Guillain-Barre syndrome. Arch Neurol. 2001;58:1460–1464. doi: 10.1001/archneur.58.9.1460. [DOI] [PubMed] [Google Scholar]
  • 222.Kelley TW, Prayson RA, Ruiz AI, Isada CM, Gordon SM. The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature. Am J Clin Pathol. 2003;119:749–753. doi: 10.1309/PU4R-76JJ-MG1F-81RP. [DOI] [PubMed] [Google Scholar]
  • 223.Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during late summer of 2003. Can J Neurol Sci. 2004;31:194–203. doi: 10.1017/s031716710005383x. [DOI] [PubMed] [Google Scholar]
  • 224.Roos K. Fever and asymmetrical weakness in the Summer: evidence of a West Nile virus-associated poliomyelitis-like illness. Mayo Clin Proc. 2003;78:1205–1206. doi: 10.4065/78.10.1205. [DOI] [PubMed] [Google Scholar]
  • 225.Ben-Nathan D, Lustig S, Tam G, Robinson S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Inf Dis. 2003;188:5–12. doi: 10.1086/376870. [DOI] [PubMed] [Google Scholar]
  • 226.Pyrgos V, Younus F. High-dose steroids in the management of acute flaccid paralysis due to West Nile virus infection. Scan J Infect Dis. 2004;36:509–512. doi: 10.1080/00365540410020659. [DOI] [PubMed] [Google Scholar]
  • 227.Gorson KC, Ropper AH. Acute respiratory failure in neuropathy: a variant of critical illness polyneuropathy. Crit Care Med (letter) 1993;21:1986–1987. doi: 10.1097/00003246-199312000-00042. [DOI] [PubMed] [Google Scholar]
  • 228.Young GB, Hammond RR. A stronger approach to weakness in the intensive care unit. Crit Care. 2004;6:416–418. doi: 10.1186/cc2961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 229.Bolton CF, Breuer AC. Critical illness polyneuropathy. Muscle Nerve. 1999;22:419–424. doi: 10.1002/(SICI)1097-4598(199903)22:3&#x0003c;419::AID-MUS18&#x0003e;3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 230.Prielipp RC, Coursin DB. Applied pharmacology of common neuromuscular blocking agents in critical care. New Horizons. 1994;2:34–47. [PubMed] [Google Scholar]

Articles from Neurocritical Care are provided here courtesy of Nature Publishing Group

RESOURCES